Cancer molecular diagnostics company GenCurix has been on the rise for two consecutive days. The news that the Dropplex lung cancer panel test was selected as a poster abstract at the World Conference on Lung Cancer (WCLC) appears to be influencing the stock price.
As of 9:54 a.m. on the 16th, GenCurix is trading at 3,890 KRW, up 19.69% from the previous trading day.
The Dropplex panel demonstrated a 91% concordance rate with next-generation sequencing (NGS) diagnostic methods in a clinical study involving 35 patients with non-small cell lung cancer (NSCLC).
Jongseok Jeong, Head of Global Business at GenCurix, introduced the Dropplex lung cancer panel test as "a diagnostic method that can target diagnostic demands and markets unmet by existing PCR or NGS testing methods."
Clinicians involved in the study analyzed that the three mutations that did not match were not targets of the panel and also did not affect drug safety and efficacy. Following this study, GenCurix is conducting larger-scale additional research to evaluate and expand the clinical validity of the Dropplex panel.
Compared to NGS, the Dropplex panel offers advantages such as a simplified workflow, faster processing time, lower sample input requirements, high sensitivity and specificity, and cost savings, making it an effective first-line diagnostic tool for detecting mutations in non-small cell lung cancer, which accounts for 85% of all lung cancers.
As a digital nucleic acid amplification device (digital PCR) product utilizing plasma nucleic acids, it enables efficient patient management through monitoring with patient blood before and after surgery and treatment.
WCLC is a conference hosted by the International Association for the Study of Lung Cancer (IASLC). It will be held in San Diego, USA, from the 7th to the 10th of next month. Since January this year, GenCurix has been an official partner of IASLC. IASLC is a top-level global network dedicated to research and eradication of lung cancer and other thoracic malignancies, involving over 8,000 experts from 100 countries worldwide. GenCurix plans to actively participate in IASLC’s pilot projects.
Head Jeong stated, "At the ASCO Breakthrough event on the 6th, we emphasized the technological development and excellent performance of the Dropplex panel," adding, "We will present comparative research results with NGS testing methods at the World Conference on Lung Cancer." He further added, "We are preparing concrete plans for clinical trials with leading clinicians of the World Conference on Lung Cancer and FDA approval to enter the U.S. market."
The U.S. market for lung cancer companion diagnostics and treatment monitoring is showing an annual growth rate of over 17%. It is expected to grow into a market worth approximately 3 trillion KRW by 2030.
GenCurix’s subsidiary NanobioLife has developed an integrated all-in-one real-time qPCR (‘All-in-One PCR’) that performs nucleic acid isolation, amplification, and analysis fully automatically in one step after sample input. The All-in-One PCR is a diagnostic device capable of diagnosing various viral infectious diseases such as COVID-19 and HPV, which causes cervical cancer, sexually transmitted diseases, malaria, and dengue fever within 1 to 2 hours. NanobioLife’s All-in-One PCR is the world’s first to feature an ultra-fast CAM (CAM) type nucleic acid extraction processing automation module, maximizing extraction efficiency. It was developed as an open system that can use all existing PCR reagents without being housed in a separate dedicated cartridge, solving reagent compatibility issues.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
